Brown Advisory Inc. Sells 1,238 Shares of Regeneron Pharmaceuticals Inc (REGN)

Brown Advisory Inc. lessened its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 39.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,922 shares of the biopharmaceutical company’s stock after selling 1,238 shares during the period. Brown Advisory Inc.’s holdings in Regeneron Pharmaceuticals were worth $717,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Whittier Trust Co. raised its holdings in Regeneron Pharmaceuticals by 195.7% during the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 45 shares during the period. Rehmann Capital Advisory Group increased its stake in Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 68 shares during the period. AdvisorNet Financial Inc increased its stake in Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 52 shares during the period. Intercontinental Wealth Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $33,000. Finally, Blume Capital Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Institutional investors own 66.79% of the company’s stock.

A number of analysts have weighed in on the company. BidaskClub lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals to $412.00 and gave the stock a “market perform” rating in a research note on Thursday, February 7th. Piper Jaffray Companies increased their target price on Regeneron Pharmaceuticals to $487.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Finally, ValuEngine upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 15th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $413.76.



Shares of Regeneron Pharmaceuticals stock opened at $391.80 on Friday. The firm has a market cap of $42.82 billion, a PE ratio of 19.79, a PEG ratio of 1.56 and a beta of 1.20. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, beating the consensus estimate of $5.10 by $1.74. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.23 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current year.

In other news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 1,791 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total value of $734,310.00. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $5,786,740. The disclosure for this sale can be found here. Company insiders own 12.42% of the company’s stock.

WARNING: This story was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://dakotafinancialnews.com/2019/03/24/brown-advisory-inc-sells-1238-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Conference Calls and Individual Investors

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.